Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afluria Quad/Afluria Quad Junior pediatric safety and reactogenicity study
ACTRN12619000792123Phase 4Terminated
- Sponsor
- CSL Seqirus
- Start
- May 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of influenza B virus B/Brisbane/46/2015 antigen (propiolactone inactivated) and Afluria in influenza (2 arms), sponsored by CSL Seqirus. Primary endpoints: Frequency, intensity and duration of solicited local adverse reactions and Frequency, intensity and duration of solicited systemic reactions. Started May 2019; status: terminated.
02
Drugs
influenza B virus B/Brisbane/46/2015 antigen (propiolactone inactivated)Afluria
03
Conditions
influenza
Beyond the preview
Go deeper on ACTRN12619000792123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619000792123.